Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
GE HealthCare Technologies's 3-Year RORE % for the quarter that ended in Mar. 2026 was 8.18%.
The industry rank for GE HealthCare Technologies's 3-Year RORE % or its related term are showing as below:
MEX:GEHC's 3-Year RORE % is ranked better than 61.13% of 777
companies
in the Medical Devices & Instruments industry
Industry Median: -4.03
vs MEX:GEHC: 8.18
GE HealthCare Technologies (MEX:GEHC) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
GE HealthCare Technologies 3-Year RORE % Related Terms
GE HealthCare Technologies 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GEHC vs DXCM, STE, ZBH: 3-Year RORE % Comparison
For the Medical Devices subindustry, GE HealthCare Technologies's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GE HealthCare Technologies 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, GE HealthCare Technologies's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where GE HealthCare Technologies's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
GE HealthCare Technologies (MEX:GEHC) has a 3-Year RORE % of 8.18 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on GE HealthCare Technologies and its competitors. According to the industry distribution chart, GE HealthCare Technologies ranks #302 out of 777 companies in the Medical Devices & Instruments industry, placing it in the top 38.9%.
Is GE HealthCare Technologies' 3-Year RORE % too high?
GE HealthCare Technologies' current 3-Year RORE % is 8.18. Based on the distribution chart, GE HealthCare Technologies ranks #302 out of 777 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, GE HealthCare Technologies has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GE HealthCare Technologies' 3-Year RORE % compare to DXCM and STE?
According to the Medical Devices & Instruments industry distribution chart, GE HealthCare Technologies ranks #302 out of 777 companies for 3-Year RORE %. This puts GE HealthCare Technologies in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on GE HealthCare Technologies and its competitors. GE HealthCare Technologies's current 3-Year RORE % is 8.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GE HealthCare Technologies stock overvalued right now?
Based on GuruFocus' analysis, GE HealthCare Technologies (MEX:GEHC) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,490.82, compared to a current price of MXN1,149.89 — trading 22.9% below its estimated fair value. The current 3-Year RORE % is 8.18. GE HealthCare Technologies' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For GE HealthCare Technologies (MEX:GEHC), the current 3-Year RORE % is 8.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GE HealthCare Technologies (MEX:GEHC) Overvalued in 2026?
Based on GuruFocus' analysis, GE HealthCare Technologies stock appears to be undervalued.
The current stock price of MXN1,149.89 is trading 22.9% below its estimated GF Value™ of MXN1,490.82.
GuruFocus considers GE HealthCare Technologies to be Modestly Undervalued.
Key valuation signals for MEX:GEHC:
3-Year RORE %: 8.18
GF Value™: MXN1,490.82 vs. price of MXN1,149.89 (22.9% below fair value)
No single metric tells the full story. See the MEX:GEHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
63GF Score
Get the complete analysis for MEX:GEHC
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GEHC has been successfully added to your 
